A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Condition: HER2-positive Breast Cancer Intervention: Drug: Eribulin mesylate injection、Pertuzumab、Trastuzumab Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab emtansine Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Condition: HER2-positive Breast Cancer Intervention: Drug: Eribulin mesylate injection、Pertuzumab、Trastuzumab Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab emtansine Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Condition: HER2-positive Breast Cancer Intervention: Drug: Eribulin mesylate injection、Pertuzumab、Trastuzumab Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab emtansine Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Condition: HER2-positive Breast Cancer Intervention: Drug: Eribulin mesylate injection、Pertuzumab、Trastuzumab Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab emtansine Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Condition: HER2-positive Breast Cancer Intervention: Drug: Eribulin mesylate injection、Pertuzumab、Trastuzumab Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer
Condition: Breast Cancer Intervention: Drug: Trastuzumab emtansine Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 14, 2023 Category: Research Source Type: clinical trials
